|
Dr. Shlevin is the President & CEO of Tikvah Therapeutics, Inc., a pharmaceutical enterprise focused on late-stage development of compounds with strong intellectual property protection and significant market potential. Its primary development focus is on the novel application of existing therapeutic entities where clinical proof of concept is already well-established and its commercial focus is in the specialty areas of CNS - psychiatry and neurology . Prior to this, Dr. Shlevin held the position of Global Senior Vice President, and a member of the boards of Solvay Pharmaceutical, SA and Solvay Pharmaceuticals Inc. He has also held a variety of other positions with Solvay Pharmaceuticals including President & Chief Executive Officer, and Senior Vice President of Business Development and Scientific Affairs. Dr. Shlevin has over two decades of diverse healthcare business-related experience, involving virtually every aspect of the pharmaceutical business from research and development to commercial operations. He was also a member of the management committee, an officer of the corporation, and Chairman of the Board of its independently owned and operated subsidiary Unimed Pharmaceuticals, Inc. In addition to this he was a member of the global pharmaceutical management committee for Solvay Pharmaceuticals Inc., the consortium of Solvay S.A.’s worldwide pharmaceutical business, and a member of the board of Solvay Draka. His past industry experience includes leadership roles at G.D. Searle and Co., Ciba-Geigy Corp. and he was a founder of Ciba Vision.Ophthalmics. Dr. Shlevin’s experience related to his responsibilities as an audit committee member include his tenure as CEO of Solvay and as Senior Vice President where he was regularly involved in assessments and analysis of financial statements and projections and acquisitions of companies and of products.
| 